← Back to patent-cliff list
Latanoprost
Tier C — Watch / tradeLatanoprost
Pfizer Inc.
Originator
1996
First approval
-
Expiry (public)
$0.23B ▲
Peak sales
Small molecule
Type
Targets：PTGFR
Brand：MicroProst, Latoprost, Xelpros, Monoprost, Catioprost, Xalatan, Eye-D
Indications (approved)：Ocular hypertension, Open-angle glaucoma
Regional status
US
Approved
1996-06-05
EU
Approved
2023-11-15
China
Approved
1999-02-13
Japan
Approved
1999-03-12
Synthetic routes & intermediates4 routes
Originator routes × 1Optimised (non-patent) × 3Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OriginatorRoute 1Steps 8 · Total yield 0.19 g
LATA-00131752-99-5LATA-00238754-71-1LATA-00341162-19-0LATA-00441639-72-9LATA-00541639-73-0LATA-006145667-74-9LATA-007145667-75-0LATA-008352276-28-9LATA-00917814-85-6LATA-01041639-83-2LATA-01175-30-9API · Latanoprost
| Code | CAS No. | Intermediate |
|---|---|---|
| LATA-001 | 31752-99-5 | (3aR,4S,5R,6aS)-4-(hydroxymethyl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl [1,1'-biphenyl]-4-carboxylate |
| LATA-002 | 38754-71-1 | (3aR,4R,5R,6aS)-4-formyl-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl [1,1'-biphenyl]-4-carboxylate |
| LATA-003 | 41162-19-0 | dimethyl (2-oxo-4-phenylbutyl)phosphonate |
| LATA-004 | 41639-72-9 | (3aR,4R,5R,6aS)-2-oxo-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl [1,1'-biphenyl]-4-carboxylate |
| LATA-005 | 41639-73-0 | (3aR,4R,5R,6aS)-4-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl [1,1'-biphenyl]-4-carboxylate |
| LATA-006 | 145667-74-9 | (3aR,4R,5R,6aS)-4-((R)-3-hydroxy-5-phenylpentyl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl [1,1'-biphenyl]-4-carboxylate |
| LATA-007 | 145667-75-0 | (3aR,4R,5R,6aS)-5-hydroxy-4-((R)-3-hydroxy-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-one |
| LATA-008 | 352276-28-9 | (3aR,4R,5R,6aS)-4-((R)-3-hydroxy-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2,5-diol |
| LATA-009 | 17814-85-6 | (4-carboxybutyl)triphenylphosphonium bromide |
| LATA-010 | 41639-83-2 | (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid |
| LATA-011 | 75-30-9 | 2-iodopropane |
OptimisedRoute 2Steps 10 · Total yield /
LATA-008352276-28-9LATA-00917814-85-6LATA-01041639-83-2LATA-01175-30-9LATA-012591-87-7LATA-013122-97-4LATA-01498088-55-2LATA-0151379822-84-0LATA-016474944-31-5LATA-017876953-73-0LATA-018110-02-1LATA-019—LATA-020—LATA-0211644539-27-4LATA-0221644539-31-0API · Latanoprost
| Code | CAS No. | Intermediate |
|---|---|---|
| LATA-008 | 352276-28-9 | (3aR,4R,5R,6aS)-4-((R)-3-hydroxy-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2,5-diol |
| LATA-009 | 17814-85-6 | (4-carboxybutyl)triphenylphosphonium bromide |
| LATA-010 | 41639-83-2 | (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid |
| LATA-011 | 75-30-9 | 2-iodopropane |
| LATA-012 | 591-87-7 | allyl acetate |
| LATA-013 | 122-97-4 | 3-phenylpropan-1-ol |
| LATA-014 | 98088-55-2 | (S)-1-phenylhex-5-en-3-ol |
| LATA-015 | 1379822-84-0 | (S)-tert-butyldimethyl((1-phenylhex-5-en-3-yl)oxy)silane |
| LATA-016 | 474944-31-5 | (S)-3-((tert-butyldimethylsilyl)oxy)-5-phenylpentan-1-ol |
| LATA-017 | 876953-73-0 | (S)-tert-butyl((1-iodo-5-phenylpentan-3-yl)oxy)dimethylsilane |
| LATA-018 | 110-02-1 | thiophene |
| LATA-019 | - | - |
| LATA-020 | - | (3aR,6aS)-2-methoxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde |
| LATA-021 | 1644539-27-4 | tert-butyl(((3R)-1-((3aR,4R,6aS,Z)-2-methoxy-5-(((trimethylsilyl)oxy)methylene)hexahydro-2H-cyclopenta[b]furan-4-yl)-5-phenylpentan-3-yl)oxy)dimethylsilane |
| LATA-022 | 1644539-31-0 | (3aR,4R,5R,6aS)-4-((R)-3-((tert-butyldimethylsilyl)oxy)-5-phenylpentyl)-2-methoxyhexahydro-2H-cyclopenta[b]furan-5-ol |
OptimisedRoute 3Steps 8 · Total yield /
LATA-00341162-19-0LATA-00917814-85-6LATA-01041639-83-2LATA-02364091-14-1LATA-0241240483-13-9LATA-0251240483-14-0LATA-0261240483-20-8LATA-0271240483-21-9LATA-0281240483-22-0LATA-0291240483-23-1LATA-03067-63-0API · Latanoprost
| Code | CAS No. | Intermediate |
|---|---|---|
| LATA-003 | 41162-19-0 | dimethyl (2-oxo-4-phenylbutyl)phosphonate |
| LATA-009 | 17814-85-6 | (4-carboxybutyl)triphenylphosphonium bromide |
| LATA-010 | 41639-83-2 | (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid |
| LATA-023 | 64091-14-1 | (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-2-oxohexahydro-2H-cyclopenta[b]furan-4-carbaldehyde |
| LATA-024 | 1240483-13-9 | (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one |
| LATA-025 | 1240483-14-0 | (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one |
| LATA-026 | 1240483-20-8 | (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((R)-3-hydroxy-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-one |
| LATA-027 | 1240483-21-9 | (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((R)-3-((tert-butyldimethylsilyl)oxy)-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-one |
| LATA-028 | 1240483-22-0 | (3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((R)-3-((tert-butyldimethylsilyl)oxy)-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-ol |
| LATA-029 | 1240483-23-1 | (Z)-7-((1R,2R,3R,5S)-3-((tert-butyldimethylsilyl)oxy)-2-((R)-3-((tert-butyldimethylsilyl)oxy)-5-phenylpentyl)-5-hydroxycyclopentyl)hept-5-enoic acid |
| LATA-030 | 67-63-0 | propan-2-ol |
OptimisedRoute 4Steps 7 · Total yield 0.7 g
LATA-007145667-75-0LATA-00917814-85-6LATA-01041639-83-2LATA-01175-30-9LATA-03161263-22-7LATA-032856453-29-7LATA-033141074-03-5LATA-0341652582-57-4LATA-0351261926-71-9API · Latanoprost
| Code | CAS No. | Intermediate |
|---|---|---|
| LATA-007 | 145667-75-0 | (3aR,4R,5R,6aS)-5-hydroxy-4-((R)-3-hydroxy-5-phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-one |
| LATA-009 | 17814-85-6 | (4-carboxybutyl)triphenylphosphonium bromide |
| LATA-010 | 41639-83-2 | (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid |
| LATA-011 | 75-30-9 | 2-iodopropane |
| LATA-031 | 61263-22-7 | (3aR,4R,5R,6aS)-4-((3R)-5-phenyl-3-((tetrahydro-2H-pyran-2-yl)oxy)pentyl)-5-((tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-cyclopenta[b]furan-2-one |
| LATA-032 | 856453-29-7 | (3aR,4R,5R,6aS)-4-((3R)-5-phenyl-3-((tetrahydro-2H-pyran-2-yl)oxy)pentyl)-5-((tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-cyclopenta[b]furan-2-ol |
| LATA-033 | 141074-03-5 | (Z)-7-((1R,2R,3R,5S)-5-hydroxy-2-((3R)-5-phenyl-3-((tetrahydro-2H-pyran-2-yl)oxy)pentyl)-3-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)hept-5-enoic acid |
| LATA-034 | 1652582-57-4 | (8aR,9R,10R,11aS,Z)-9-((3R)-5-phenyl-3-((tetrahydro-2H-pyran-2-yl)oxy)pentyl)-10-((tetrahydro-2H-pyran-2-yl)oxy)-4,5,8,8a,9,10,11,11a-octahydrocyclopenta[b]oxecin-2(3H)-one |
| LATA-035 | 1261926-71-9 | (8aR,9R,10R,11aS,Z)-10-hydroxy-9-((R)-3-hydroxy-5-phenylpentyl)-4,5,8,8a,9,10,11,11a-octahydrocyclopenta[b]oxecin-2(3H)-one |
Frequently asked questions
What are the approved indications of Latanoprost?
Approved indications include: Ocular hypertension, Open-angle glaucoma.
When does the Latanoprost patent expire?
No public expiry year is available for Latanoprost yet; this page updates once verified.
How many synthesis routes are recorded for Latanoprost?
4 synthesis routes are recorded; the shortest is 7 steps with 0.7 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Latanoprost intermediates?
All intermediates in Latanoprost routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Latanoprost intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29